Replimune Group, Inc.·4

Apr 7, 9:10 PM ET

Astley-Sparke Philip 4

4 · Replimune Group, Inc. · Filed Apr 7, 2026

Research Summary

AI-generated summary of this filing

Updated

Replimune (REPL) Director Philip Astley‑Sparke Receives Stock Awards

What Happened
Philip Astley‑Sparke, a director of Replimune Group, received equity awards on April 1, 2026. The filing reports two grants: 50,000 restricted stock units (RSUs) and 75,000 derivative awards (stock option-type award), both issued at $0.00 per share (no cash paid).

Key Details

  • Transaction date: 2026-04-01. Both entries are coded "A" (award/grant).
  • Consideration: $0.00 per share; total cash value reported = $0 (these are compensation awards, not open‑market purchases).
  • Vesting / terms:
    • RSUs (50,000): each RSU converts to one share; 25% vest on May 15, 2027, remainder vests in three roughly equal annual installments through May 15, 2030. (Footnote F1)
    • Derivative award (75,000): 25% of the shares vest on April 1, 2027; remaining shares vest in ~36 equal monthly installments thereafter. (Footnote F2)
  • Shares owned after transaction: not specified in this Form 4.
  • Filing timeliness: This Form 4 was filed late due to an inadvertent administrative error (timeliness flag: L). Late filing delays public disclosure of insider activity and reduces near‑term transparency.

Context

  • These are compensation grants to a director (not open‑market purchases or sales). Awards at $0 typically reflect standard equity compensation and do not necessarily signal an immediate bullish or bearish trading intent.
  • The derivative entry appears to be a time‑vested option‑style award; no exercise or immediate sale was reported.

Insider Transaction Report

Form 4
Period: 2026-04-01
Transactions
  • Award

    Common Stock

    [F1]
    2026-04-01+50,0001,430,071 total
  • Award

    Stock Option (right to buy)

    [F2]
    2026-04-01+75,00075,000 total
    Exercise: $7.61Exp: 2036-04-01Common Stock (75,000 underlying)
Footnotes (2)
  • [F1]Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
  • [F2]25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Signature
/s/ Shawn Glidden, attorney-in-fact|2026-04-07

Documents

1 file
  • 4
    tm2611350-14_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT